Premium
Human manganese superoxide dismutase suppresses HER2/neu‐mediated breast cancer malignancy
Author(s) -
Chuang Tzu-Chao,
Liu Jah-Yao,
Lin Chi-Tsai,
Tang Ya-Ting,
Yeh Ming-Han,
Chang Su-Chien,
Li Jhy-Wei,
Kao Ming-Ching
Publication year - 2007
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2007.08.021
Subject(s) - cancer research , transfection , her2/neu , malignancy , superoxide dismutase , oncogene , breast cancer , in vivo , cancer , in vitro , breast carcinoma , biology , cell culture , microbiology and biotechnology , chemistry , medicine , endocrinology , cell cycle , biochemistry , oxidative stress , genetics
The up‐regulation of HER2/neu is associated with human malignancies and is a useful target for developing anticancer drugs. Overexpression of human manganese superoxide dismutase (MnSOD) has been demonstrated to effectively suppress various carcinoma cells, including breast carcinomas, in vitro and in vivo. This study demonstrates that MnSOD effectively suppresses HER2/ neu oncogene expression at the transcriptional level. Additionally, stable transfection was used and the MnSOD‐transfected human breast cancer clones were found to be able to down‐regulate the endogenous production of p185 HER2/neu . Furthermore, the MnSOD‐overexpressing stable transfectants exhibited reduced soft‐agarose colony‐forming ability and metastatic properties, unlike control cell lines. These data suggest that MnSOD may be useful in treating HER2/neu‐mediated human breast tumor malignancy.